Search details
1.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
N Engl J Med
; 388(8): 719-732, 2023 02 23.
Article
in English
| MEDLINE | ID: mdl-36795891
2.
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Lancet Oncol
; 23(10): 1297-1307, 2022 10.
Article
in English
| MEDLINE | ID: mdl-36063830
3.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 816-826, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31047803
4.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 19(7): 975-986, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29880291
5.
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors.
Anticancer Drugs
; 26(4): 448-55, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25643049
6.
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome.
JCO Precis Oncol
; 8: e2300265, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38271657
7.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N Engl J Med
; 363(5): 411-22, 2010 Jul 29.
Article
in English
| MEDLINE | ID: mdl-20818862
8.
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Lung Cancer
; 163: 19-26, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34894455
9.
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
J Immunother Cancer
; 8(2)2020 09.
Article
in English
| MEDLINE | ID: mdl-32907924
10.
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Cancer Discov
; 10(5): 688-701, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32213540
11.
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
J Clin Oncol
; 38(17): 1887-1896, 2020 06 10.
Article
in English
| MEDLINE | ID: mdl-32058843
12.
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 21(17): 3862-9, 2015 Sep 01.
Article
in English
| MEDLINE | ID: mdl-25925891
13.
Reply to T.J.A. Dekker.
J Clin Oncol
; 38(28): 3351-3352, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-32658630
14.
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Cancer Chemother Pharmacol
; 74(6): 1251-60, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25344761
15.
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.
Cancer Chemother Pharmacol
; 68(2): 547-52, 2011 Aug.
Article
in English
| MEDLINE | ID: mdl-21516509
16.
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
J Immunother
; 33(2): 178-84, 2010.
Article
in English
| MEDLINE | ID: mdl-20145546
17.
Tools for dissecting signaling pathways in vivo: receptors activated solely by synthetic ligands.
Methods Enzymol
; 343: 232-48, 2002.
Article
in English
| MEDLINE | ID: mdl-11665570
18.
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
J Clin Oncol
; 25(6): 669-74, 2007 Feb 20.
Article
in English
| MEDLINE | ID: mdl-17308271
19.
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol
; 24(19): 3089-94, 2006 Jul 01.
Article
in English
| MEDLINE | ID: mdl-16809734
20.
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
J Clin Oncol
; 24(19): 3107-12, 2006 Jul 01.
Article
in English
| MEDLINE | ID: mdl-16754937